(Q30402402)

21 June 2017

Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial (English)

1 reference

21 June 2017

0 references

0 references

Annelies Wilder-Smith

8

0 references

Lawrence Soon-U Lee

object named as

Lawrence Lee

2

0 references

Eng Eong Ooi

object named as

Eng Eong Ooi

4

0 references

author name string

Nicholas I Paton

1

1 reference

21 June 2017

Ying Xu

3

1 reference

21 June 2017

Yin Bun Cheung

5

1 reference

21 June 2017

Sophia Archuleta

6

1 reference

21 June 2017

Gerard Wong

7

1 reference

21 June 2017

5 May 2011

1 reference

Lancet Infectious Diseases

21 June 2017

1 reference

21 June 2017

11

1 reference

21 June 2017

9

1 reference

21 June 2017

677-683

1 reference

Strategies for mitigating an influenza pandemic

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Vaccines for preventing influenza in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Major issues and challenges of influenza pandemic preparedness in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Effects of chloroquine on viral infections: an old drug against today's diseases?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

In vitro inhibition of human influenza A virus replication by chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Chloroquine is effective against influenza A virus in vitro but not in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Confronting an influenza pandemic with inexpensive generic agents: can it be done?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Meeting the challenge of influenza pandemic preparedness in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Detection of novel (swine origin) H1N1 influenza A virus by quantitative real-time reverse transcription-PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Pandemic potential of a strain of influenza A (H1N1): early findings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Interpreting vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970065-2

7 January 2021

10.1016/S1473-3099(11)70065-2

Identifiers

DOI

1 reference

21 June 2017

1 reference